Investigational drug · Phase 3
HEC585
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF), Idiopathic Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF).
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
9
Any phase or sponsor naming "HEC585"
First trial start
2021
Jun 30, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HEC585", any sponsor or status.
Conditions studied
As listed on its trial records.
- Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
- Idiopathic Pulmonary Fibrosis
- Idiopathic Pulmonary Fibrosis (IPF)
Approved drugs for the same conditions: Idiopathic pulmonary fibrosis · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "HEC585" as an intervention, largest first.
- Confirmatory Clinical Study of HEC585 Tablets in Patients With IPFPivotal-lookingRecruiting
Sunshine Lake Pharma Co., Ltd.Industry
NCT07082842 · 472 participants (planned) · Start Oct 27, 2025 · Primary completion Jan 15, 2031
Drug: HEC585; Placebo and 1 more · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Beijing, China
- Phase ll Study of HEC585 in Patients With IPFPivotal-lookingActive, not recruiting
Sunshine Lake Pharma Co., Ltd.Industry
NCT05060822 · 270 participants (planned) · Start Jun 30, 2021 · Primary completion Jul 16, 2025
Drug: HEC585; Pirfenidone and 1 more · For: Idiopathic Pulmonary Fibrosis
Sites: Beijing, China
- The Safety, Tolerability and Pharmacokinetic Study of HEC585 in Healthy Male and Female SubjectsPivotal-lookingCompleted
Sunshine Lake Pharma Co., Ltd.Industry
NCT03092102 · 136 participants · Start May 20, 2017 · Primary completion Feb 25, 2019
Drug: HEC585 · For: Idiopathic Pulmonary Fibrosis
Sites: Madison, Wisconsin
- A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) PatientsPivotal-lookingRecruiting
Sunshine Lake Pharma Co., Ltd.Industry
NCT05139719 · 110 participants (planned) · Start Feb 15, 2023 · Primary completion Dec 2026
Drug: HEC585 dose A; HEC585 dose B and 1 more · For: Progressive Fibrosing Interstitial Lung Disease (PF-ILD) / Progressive Pulmonary Fibrosis (PPF)
Sites: Beijing, China
- Single and Multiple Dose Safety, Tolerability, PK and Food Effect Study of HEC122505MsOH Tablets in Healthy Adult SubjectsPivotal-lookingCompleted
Sunshine Lake Pharma Co., Ltd.Industry
NCT04625361 · 106 participants · Start Jan 20, 2021 · Primary completion Jan 6, 2022
Drug: HEC122505MsOH · For: Parkinson Disease
Sites: Shanghai, China
Sunshine Lake Pharma Co., Ltd.Industry
NCT04512170 · 72 participants · Start Jul 13, 2020 · Primary completion Aug 23, 2021
Drug: HEC585; placebo · For: Idiopathic Pulmonary Fibrosis
Sites: Shanghai, China
Sunshine Lake Pharma Co., Ltd.Industry
NCT05383131 · 33 participants · Start Jun 23, 2021 · Primary completion Nov 30, 2021
Drug: HEC585; Pirfenidone and 1 more · For: Idiopathic Pulmonary Fibrosis
Sites: Shanghai, China
- Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy SubjectsCompleted
Sunshine Lake Pharma Co., Ltd.Industry
NCT07588646 · 33 participants · Start Jun 29, 2021 · Primary completion Nov 30, 2021
Drug: HEC585; Nintedanib and 1 more · For: Idiopathic Pulmonary Fibrosis
Sites: Shanghai, China
Sunshine Lake Pharma Co., Ltd.Industry
NCT05468346 · 6 participants · Start Jul 26, 2022 · Primary completion Aug 14, 2022
Drug: [14C]-HEC585 · For: Healthy Volunteer
Sites: Suzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- A Phase I Study Assessing the Safety, Tolerability, and Pharmacokinetics of Yinfenidone: A Novel, Potent Drug for Idiopathic Pulmonary Fibrosis Treatment in Healthy Chinese Subjects.
Ou M, Zhuang Y, Zhu H, et al. · Clin Ther 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.